The beneficial effect of branched-chain amino acids with simeprevir with peginterferon alpha-2b plus ribavirin for chronic hepatitis C

INTERVENTION: Patients were treated by simeprevir plus peginterferon/ribavirin therapy with BCAA enriched supplement. Patients were treated by simeprevir plus peginterferon/ribavirin therapy without BCAA enriched supplement. CONDITION: Chronic hepatitis type C PRIMARY OUTCOME: Sustained virological response SECONDARY OUTCOME: 1) Negative conversion rate of HCV‐RNA (at 4W, 12W, 24W of therapy); 2) Change in hemoglobin; 3) Dose of drug (simeprevir, peginterferon, ribavirin); 4) Improvement of insulin resistance; 5) Improvement of loss of zinc ; 6) Improvement of BTR; 7) Occurrence of side effect INCLUSION CRITERIA: 1) patients who infected HCV‐serotype1 2) age, over 20 years old and under 75 years old 3) male and female 4) patients who don't diagnosed cirrhosis by imaging or blood examination 5) patients who has no HCC by imaging examination